
Grandbrothers/iStock Editorial via Getty Images
Lantheus Holdings (NASDAQ:LNTH) announced on Wednesday that the U.S. Food and Drug Administration (FDA) accepted its marketing application for a new formulation of its F 18 PSMA radioactive imaging agent.
The New Drug Application filed by Lantheus’ (NASDAQ:LNTH) affiliate